A retrospective study of the safety and efficacy of paclitaxel plus ramucirumab in patients with advanced or recurrent gastric cancer with ascites

Table 3 Adverse events of special interest for ramucirumab

	All (N = 83) (%)		No ascites (N = 43) (%)		Small to moderate ascites (N = 26) (%)		Massive ascites (N = 14) (%)		P value*
	All (%)	≥ Gr3(%)	All (%)	≥ Gr3(%)	All (%)	≥ Gr3(%)	All (%)	≥ Gr3(%)	P value*
Hypertension	24 (29)	2 (2)	11 (26)	0	10 (38)	1 (4)	3 (21)	1 (7)	0.27
Bleeding or haemorrhage	19 (23)	2 (2)	9 (21)	2 (5)	6 (23)	0	4 (29)	0	0.39
Proteinuria	9 (11)	0	4 (9)	0	5 (19)	0	0	0	0.16**
Liver injury or failure	6 (7)	0	2 (5)	0	2 (8)	0	2 (14)	0	0.48**
Gastrointestinal haemorrhage	5 (6)	2 (2)	3 (7)	2 (5)^a	1 (4)	0	1 (7)	0	0.39
Gastrointestinal perforation	1 (1)	1 (1)	0	0	1 (4)	1 (4)	0	0	0.33
Infusion-related reaction	0	0	0	0	1 (4)	0	0	0	0.33**

*Comparison in grade 3 or more
**Comparison in all grades
^aOne patient died due to peritoneal metastasis which infiltrated to small intestine

ISSN: 1471-2407